Breaking News
October 18, 2018 - From Biopsy to Diagnosis
October 18, 2018 - Sexual harassment and assault linked to worse physical/mental health among midlife women
October 18, 2018 - Stumped by medical school? A Q&A with a learning specialist
October 18, 2018 - Targeting immune checkpoints in microglia could reduce out-of-control neuroinflammation
October 18, 2018 - FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
October 18, 2018 - Many U.S. adults confused about primary care, study shows
October 18, 2018 - With philanthropic gifts, Stanford poised to make major advances in neurosciences | News Center
October 18, 2018 - Mice study shows antibiotics are not always necessary to cure sepsis
October 18, 2018 - Researchers discover why heart contractions are weaker in individuals with HCM
October 18, 2018 - Participation in organized sport during childhood may have long-term skeletal benefits
October 18, 2018 - Probiotic/antibiotic combination could eradicate drug-resistant bacteria
October 17, 2018 - More Socioeconomic Challenges for Hispanic Women With HIV
October 17, 2018 - 49,XXXXY syndrome – Genetics Home Reference
October 17, 2018 - Scientists uncover possible new causes of Tourette syndrome
October 17, 2018 - Girl undergoes unusual heart surgery after compassionate-use exemption | News Center
October 17, 2018 - Health Issues That Are Sometimes Mistaken for Gluten Sensitivity
October 17, 2018 - Elective induction of labor at 39 weeks may be beneficial option for women and their babies
October 17, 2018 - New smart watch algorithms can accurately monitor wearers’ sleep patterns
October 17, 2018 - Researchers demonstrate epigenetic memory transmission via sperm
October 17, 2018 - FDA, DHS announce memorandum of agreement to address cybersecurity in medical devices
October 17, 2018 - Health Tip: Know the Risks of Chicken Pox
October 17, 2018 - Immunotherapy effective against hereditary melanoma
October 17, 2018 - Researchers reveal new mechanism for how animal cells stay intact | News Center
October 17, 2018 - Alzheimer's Goes Under the Cryo-Electron Microscope
October 17, 2018 - Medicare for all? CMS chief warns program has enough problems already
October 17, 2018 - Metrohm Raman introduces Mira P handheld Raman system
October 17, 2018 - Expanding the knowledge about hippocampus to better understand cognitive deficits in MS
October 17, 2018 - Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features
October 17, 2018 - Many healthy children may have metabolic risk factors, finds study
October 17, 2018 - A new antibiotic could be a better, faster treatment for tuberculosis
October 17, 2018 - “I will not become a Robot Doctor”: A medical student vows to practice compassion
October 17, 2018 - Study findings may explain sporadic outbreaks of C. difficile infections in hospitals
October 17, 2018 - Purdue researchers develop new chemical process to find better drug ‘fits’ for patients
October 17, 2018 - Yale researchers develop way to attack RNA with small-molecule drugs
October 17, 2018 - New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug
October 17, 2018 - Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
October 17, 2018 - Nine cases of polio-like illness suspected in children in illinois
October 17, 2018 - Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries
October 17, 2018 - Patients once thought incurable can benefit from high-dose radiation therapy
October 17, 2018 - Researchers awarded grant to advance testing of experimental heroin vaccine
October 17, 2018 - Researchers examine SSRI use during pregnancy and major gestational malformations
October 17, 2018 - FDA grants Rare Pediatric Disease Designation for Immusoft’s Iduronicrin genleukocel-T
October 17, 2018 - Reliable Respiratory announces acquisition of Attleboro Area Medical Equipment
October 17, 2018 - Study reveals link between childhood abuse and higher arthritis risk in adulthood
October 17, 2018 - Research shows people over 65 are not performing enough physical activity
October 17, 2018 - FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
October 17, 2018 - Weight gain after smoking cessation linked to increased short-term diabetes risk
October 17, 2018 - Researchers find opportunity to control salt-sensitive hypertension without exercising
October 17, 2018 - Women not warned about cancer associated with breast implants
October 17, 2018 - Metrohm offers robust handheld Raman analyzer for Defense and Security
October 17, 2018 - Modeling Non-Numerical Data in Systems Biology
October 17, 2018 - Research aims to address health disparities in African-American men
October 17, 2018 - Human and cattle decoys trap outdoor-biting mosquitoes in malaria endemic regions
October 17, 2018 - High Circulating Prolactin Level Inversely Linked to T2DM Risk
October 17, 2018 - Study finds gene variant predisposes people to both Type 2 diabetes and low body weight
October 17, 2018 - Metrohm software products make it easy to comply with ALOCA and ALCOA+ guidelines
October 17, 2018 - Network of doctors identify the cause of 31 new conditions
October 17, 2018 - Notable improvement in brain cancer survival among younger patients but not much for elderly
October 17, 2018 - Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma
October 17, 2018 - Costs of Medicare Diabetes Prevention Program may be higher than expected reimbursement
October 17, 2018 - Misuse of prescription opioids or benzodiazepines associated with suicidal thoughts
October 17, 2018 - New research seeks to address sex disparities in women’s health
October 17, 2018 - C-Section Rates Have Nearly Doubled Since 2000: Study
October 17, 2018 - Talking to Your Kids About STDs
October 17, 2018 - New classification of periodontal and peri-implant diseases and conditions
October 17, 2018 - Herbert D. Kleber, Pioneer in Addiction Treatment, Dies at 84
October 17, 2018 - Health effects of smoke-filled atmosphere
October 17, 2018 - Down syndrome may hold important clues to onset of Alzheimer’s disease
October 17, 2018 - A special report on US’ aging societies
October 17, 2018 - Birth mode may have acute effects on neurodevelopment, study suggests
October 17, 2018 - Global health innovation system fails to deliver affordable treatments to patients, says report
October 17, 2018 - Simple, inexpensive test quickly detects antibiotic-resistant ‘superbugs’
October 17, 2018 - New drugs could reduce risk of heart disease when added to statins
October 17, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum
October 17, 2018 - HVP vaccination not linked with rise in teen risky sex
October 17, 2018 - Potential ‘early warning markers’ for sepsis discovered
October 17, 2018 - Who knew? Life begins (again) at 65
October 17, 2018 - Application of blood pressure guidelines ups treatment
October 17, 2018 - Stanford researchers find that small molecule may help treat enzyme deficiency
October 17, 2018 - Speed Cameras Save Money and Lives in New York City
Working Towards a Sustainable Future for the NHS

Working Towards a Sustainable Future for the NHS

image_pdfDownload PDFimage_print

An interview with Jennifer Lee, Director of Market Access and Advocacy at Janssen UK, the pharmaceutical company of Johnson & Johnson, discussing the importance of innovation in the private sector and making new technologies available to the NHS.

How are Janssen working to ensure the future of the NHS? Do you think the current system is sustainable?

The current healthcare system is not sustainable, and I think most people would agree with that. You only need to look at the rising cost of healthcare globally and the aging population in the western world to understand that the current system isn’t sustainable long-term.

Image Credit: sheff / Shutterstock

Traditionally, companies like Janssen were seen only as suppliers of the healthcare system, but that’s starting to change. We’re seeing more and more joint working initiatives and partnerships between industry, academia, patient groups, and the clinical community.

We’re interested in partnering with the NHS because they are our main customer, so if the NHS isn’t sustainable, we as a business are not sustainable – and this will prevent us from getting our medicines to the patients who need them.

One of the ways we at Janssen are helping is by making sure our medicines fit into new models of care. We’re also trying to revolutionize the medicines we develop for the NHS.

Traditionally, pharmaceutical companies looked to develop medicines that target the most severe stages of a disease, because it is easier to prove that the drug has a significant effect in these patients.

We can no longer treat diseases when a patient becomes severely ill. It’s expensive and is the reason that the NHS can no longer afford to provide the same level of service as it once could. That’s why we’re now investing in drugs that act prophylactically. We need to start thinking about living with disease, rather than dying of it.

Prophylaxis is not a new concept, just look at how long we’ve been vaccinating against infectious disease! We now need to take this approach with non-communicable diseases.

The NHS is currently facing extreme economic hardship. What steps are Janssen taking to reduce this?

For the NHS to become sustainable, we need to deliver healthcare in a completely different way. For us, this means moving away from just being a provider of pills and moving towards personalized care and prevention.

Image Credit: Manop_Phimsit / Shutterstock

Before the human genome project, for example, all blockbuster drugs such as statin were developed to give to the entire eligible patient population.

At Janssen, we are now looking to develop highly targeted, specific, personalized medicines that are much more sophisticated and used in a much smaller population of patients – to ultimately help improve outcomes.

This is only part of the solution. The amount of data collated in the UK’s health system is enormous and we’re working on initiatives that will harness this data to provide key insights.

For instance, by analyzing all of the interactions a patient has had with the healthcare system could allow doctors to tailor their treatment plan and decide which interventions to use based on other patients with a similar medical history.

This could allow clinicians within the NHS to develop more of an understanding of which drugs work in which patients, based on their genotype and phenotype. It could also save money and allows the NHS to become more efficient. They would be paying for patient outcomes, rather than the treatment itself.

We want our medicines to do what they say on the tin. We want the NHS to be able to identify cases where what we observe in clinical trials differs from real-life. It’s as simple as not charging the NHS if the treatment isn’t effective in the patient cohorts that it’s designed for.

This is called an outcomes-based guarantee, and it’s already in place for some of our most well-established medicines. I think this is the main way that we can help loosen the economic burden on the NHS.

When it comes to worldwide access to medication, there are a lot of disparities between different countries. What is the pharmaceutical industry doing to tackle this?

We use a tiered pricing model which ensures that if you live in one of the poorest countries in the world and there’s a medicine available that you could benefit from and your country has the healthcare infrastructure to deliver that treatment, you will be given access to it.

I can’t speak on behalf of other pharmaceutical companies, but I wouldn’t be surprised if we weren’t the only ones doing this. Our global pricing model is something that we are profoundly proud of, and something that is here to stay.

Dr. Janssen was the founder of Janssen. How is the work that Janssen are doing today contributing to his legacy?

Dr. Paul Janssen lived by the following words: “Patients are waiting”. I think that everyone working at Janssen believes in this. Patients are at the heart of everything we do and that’s his legacy.

Dr. Janssen was a founding father in medicines for mental health, and he believed that those patients deserved treatments that work. Mental health disorders are notoriously difficult to treat, and yet we are still in this disease area because if it was important for Dr. Janssen, it’s important to us.

Patients have always come first at Janssen – this ethos is reflected in the Johnson & Johnson Credo and is evidenced in our company each day.

For every business decision we make, we ask, is this the right thing to be doing for our patients? If the answer is no, or I’m not sure, then there’s a much deeper discussion to be had.

Over the next 100 years, how do you think patient care and the role of the clinician will change?

I think everything will change. From the way that healthcare is delivered to the way we view health and disease in general, all of it will change.

At the moment, the older population are most in need of healthcare resources. However, broadly speaking, they aren’t very comfortable with technology.

This means we aren’t there yet with making technologies such as healthcare apps a part of the NHS, and we won’t be for a while. But, as the millennial generation grows up, their ability to use technology will allow a fundamental shift in the way we deliver care.

The NHS will need to go beyond handing out pills to keep the population healthy and start moving towards technologies that can help you manage your overall health and wellbeing. This could be an app, or a wearable, for example.

The way you think about it today will be fundamentally different to the way we will think about it 10 years, 20 years, 50 years and 70 years’ time.

Clinicians are used to delivering medical care a certain way. They look for specific symptoms and treat the underlying condition whilst doing no harm. In the future, clinicians will need to develop a more holistic approach to care that takes into account the wellbeing of the patient from many different standpoints.

This all contributes to the linking together of the health and social care systems by the UK government. It’s about caring for a patient throughout their entire life. The technology is already there in some ways, but there needs to be a cultural shift in clinicians, patients, all of us. This will be the biggest barrier but could also be the biggest enabler.

A major step towards this will be patient empowerment. People are tracking the number of likes they get on pictures they upload to social media all the time. If they were given the technology to track their own health too, they would be more informed and more empowered to make lifestyle changes that will improve their overall health.

We’re already seeing this with FitBits and health apps, so it’s already happening on some level.

Patients who are informed and empowered have less interaction with the healthcare system. Treating patients who have multiple co-morbidities and who are incredibly ill is costly and often it is too late to reverse most of the damage. By monitoring the health of patients early on, physicians and patients themselves can intervene before it gets serious.

I think the future has the potential to be really exciting for healthcare in the UK, however, I am concerned about the required cultural shift.

We shouldn’t underestimate the significant changes that must take place – from how people think about themselves and their health to the shift needed in the health system, technology, and medicine – everything will eventually need to evolve.

About Jennifer Lee

“Having joined the company back in 2012, Jennifer Lee is the Director of Health Economics, Market Access, Reimbursement & Advocacy at Janssen UK, the pharmaceutical company of Johnson & Johnson. As part of her role, she has been working in partnership with healthcare systems, continually seeking to improve the way products are delivered in collaboration with regulators and governments.”

Tagged with:

About author

Related Articles